- Home
- PFL vs CRDF Comparison
PFL vs CRDF Comparison
Compare PFL & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFL
- CRDF
- Stock Information
- Founded
- PFL 2003
- CRDF 1999
- Country
- PFL United States
- CRDF United States
- Employees
- PFL N/A
- CRDF N/A
- Industry
- PFL Finance Companies
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFL Finance
- CRDF Health Care
- Exchange
- PFL Nasdaq
- CRDF Nasdaq
- Market Cap
- PFL 329.9M
- CRDF 288.7M
- IPO Year
- PFL N/A
- CRDF N/A
- Fundamental
- Price
- PFL $8.48
- CRDF $4.75
- Analyst Decision
- PFL
- CRDF Strong Buy
- Analyst Count
- PFL 0
- CRDF 3
- Target Price
- PFL N/A
- CRDF $10.33
- AVG Volume (30 Days)
- PFL 113.7K
- CRDF 971.7K
- Earning Date
- PFL 01-01-0001
- CRDF 02-27-2025
- Dividend Yield
- PFL 11.53%
- CRDF N/A
- EPS Growth
- PFL N/A
- CRDF N/A
- EPS
- PFL N/A
- CRDF N/A
- Revenue
- PFL N/A
- CRDF $688,000.00
- Revenue This Year
- PFL N/A
- CRDF $25.03
- Revenue Next Year
- PFL N/A
- CRDF N/A
- P/E Ratio
- PFL N/A
- CRDF N/A
- Revenue Growth
- PFL N/A
- CRDF 49.57
- 52 Week Low
- PFL $6.98
- CRDF $1.65
- 52 Week High
- PFL $8.62
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- PFL 48.84
- CRDF 62.77
- Support Level
- PFL $8.45
- CRDF $4.12
- Resistance Level
- PFL $8.60
- CRDF $4.38
- Average True Range (ATR)
- PFL 0.05
- CRDF 0.38
- MACD
- PFL -0.00
- CRDF 0.04
- Stochastic Oscillator
- PFL 34.21
- CRDF 80.17
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").